Literature DB >> 3190182

Relationships between renal function and disposition of oral ciprofloxacin.

A Forrest1, M Weir, K I Plaisance, G L Drusano, J Leslie, H C Standiford.   

Abstract

The relationships between creatinine clearance (CLCR) and the pharmacokinetics of oral ciprofloxacin were characterized. On the basis of these data, a dosage adjustment strategy, which incorporates the severity of infection and the size and renal function of the patient, was developed. An adaptive (feedback) control algorithm is proposed. A total of 32 subjects (8 normal, 8 anuric, and 16 with CLCR between 0.53 and 4.3 liters/h per 1.73 m2) were given a single 750-mg tablet of ciprofloxacin by mouth. Serial serum and urine samples were collected, assayed by high-pressure liquid chromatography, and comodeled. The population relationship between total apparent ciprofloxacin clearance (CL/f) and CLCR, both measured in liters per hour per 1.73 m2, was CL/f = 2.83 x CLCR + 21.8 (r = 0.69; P less than 0.001). The mean terminal half-life was not significantly related to CLCR but was much more variable in subjects with CLCR less than 3 liters/h per 1.73 m2 (F = 4.8; P less than 0.005). We conclude that patients with CLCR less than 1.2 liters/h per 1.73 m2 should receive two-thirds of the normal daily dose and that the dose interval should not be lengthened.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3190182      PMCID: PMC175914          DOI: 10.1128/AAC.32.10.1537

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Determination of ciprofloxacin in biological samples by reversed-phase high performance liquid chromatography.

Authors:  F Vallée; M LeBel; M G Bergeron
Journal:  Ther Drug Monit       Date:  1986       Impact factor: 3.681

2.  Absolute oral bioavailability of ciprofloxacin.

Authors:  G L Drusano; H C Standiford; K Plaisance; A Forrest; J Leslie; J Caldwell
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

3.  Dose ranging study and constant infusion evaluation of ciprofloxacin.

Authors:  G L Drusano; K I Plaisance; A Forrest; H C Standiford
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

4.  Effect of dose size on bioavailability of ciprofloxacin.

Authors:  K I Plaisance; G L Drusano; A Forrest; C I Bustamante; H C Standiford
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

5.  Forecasting individual pharmacokinetics.

Authors:  L B Sheiner; S Beal; B Rosenberg; V V Marathe
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

6.  A program package for simulation and parameter estimation in pharmacokinetic systems.

Authors:  D Z D'Argenio; A Schumitzky
Journal:  Comput Programs Biomed       Date:  1979-03

7.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

8.  Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

9.  In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent.

Authors:  G M Eliopoulos; A Gardella; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

10.  Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function.

Authors:  T C Gasser; S C Ebert; P H Graversen; P O Madsen
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

View more
  6 in total

Review 1.  Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials.

Authors:  A Aminimanizani; P Beringer; R Jelliffe
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  Effect of renal function on the bioavailability of ciprofloxacin.

Authors:  K I Plaisance; G L Drusano; A Forrest; M R Weir; H C Standiford
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

Review 3.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

5.  Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study.

Authors:  Heino Stass; Johannes Nagelschmitz; Stefan Willmann; Heinz Delesen; Abhishek Gupta; Sybille Baumann
Journal:  Clin Drug Investig       Date:  2013-06       Impact factor: 2.859

6.  Dosing regimens of oral ciprofloxacin for children with severe malnutrition: a population pharmacokinetic study with Monte Carlo simulation.

Authors:  Nahashon Thuo; Wanchana Ungphakorn; Japhet Karisa; Simon Muchohi; Alex Muturi; Gilbert Kokwaro; Alison H Thomson; Kathryn Maitland
Journal:  J Antimicrob Chemother       Date:  2011-08-10       Impact factor: 5.790

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.